Tobacco Treatment in the Context of Lung Cancer Screening

Study summary

The proposed study will test a medication plus text messaging intervention specifically designed for lung cancer screening patients. Half of the patients will receive standard of care, and half will receive the treatment intervention.

Ask AI to explain this study

Start here

Key things to know

Main goalTreatment

This describes the study’s primary purpose.

What is being studiedText messaging plus nicotine replacement therapy and Standard Care at Lung Cancer Screening

The study team can explain what participation involves.

Who it may be forSmoking Cessation

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Nov 22, 2024 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Medical University of South Carolina

Study sponsor

Study overview

What this study is about

Purpose: Treatment
Study type: Interventional
Phase: Not applicable
Sponsor: Medical University of South Carolina
Interventions being studied: Behavioral: Text messaging plus nicotine replacement therapy; Other: Standard Care at Lung Cancer Screening

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Treatment approach

Supportive or behavioral care→

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Inclusion: 1. 55 years or older 2. 30 pack year history of smoking 3. current smoker (defined as breath carbon monoxide\>6ppm) 4. willing to be randomized 5. English speaking Exclusion: 1. unstable psychiatric/medical conditions such as suicidal ideation, acute psychosis, severe alcohol dependence, substance abuse, or dementia 2. in the immediate (within 2 weeks) post myocardial infarction period 3. serious arrhythmias 4. unstable angina pectoris 5. hemodynamically or electrically unstable 6. currently taking part in any other tobacco treatment program or using cessation medication (i.e., taking NRT or other cessation medications, enrolled in the Quitline, in another drug study).

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Medical University of South CarolinaCharleston, South Carolina

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Nov 22, 2024. Always confirm current availability with the study team.

View original record ↗